Background: The COVID-19 pandemic may have been accompanied by an increased exposure to psychosis risk factors. We used a pre-during-post study design to examine variations in the incidence of First-Episode Psychosis (FEP) before, during, and after the COVID-19 pandemic in South London. We hypothesised that FEP rates rose during the pandemic and subsequently returned to pre-pandemic levels.
Methods: Using the Clinical Record Interactive Search (CRIS) system, we screened individuals referred for FEP to Early Intervention Services for Psychosis (EISs) of the South London and Maudsley NHS Foundation Trust (SLaM) from 1 March 2018 to 29 February 2024. Population data for the SLaM catchment area were obtained from the Office for National Statistics (ONS). We calculated crude incidence rates and used Poisson regression models to estimate age-sex-ethnicity-adjusted variation in incidence by year (March-to-February) expressed as Incidence Rate Ratios (IRR).
Findings: A total of 3752 individuals experienced FEP during 5,487,858 person-years at risk, with a mean crude incidence of 68.4 per 100,000 person-years (95% CI: 66.2-70.6). The Poisson model showed a deviation from this mean at the peak of the COVID-19 pandemic in 2020/21, with FEP rates rising to 77.5 per 100,000 person-years (95% CI: 71.8-83.2) and similar rates in 2021/22. FEP incidence gradually returned to the pre-pandemic levels in the following years. During the COVID-19 pandemic, individuals of Black ethnicity experienced the greatest FEP increase, with an IRR of 1.45 (95% CI: 1.29-1.61) in 2020/21 and similar ratios in 2021/22. An increase was also observed in Asian individuals, with an IRR of 1.54 (95% CI: 1.20-1.88) in 2021/22, whereas no significant changes in incidence were observed for other ethnic groups across the pre-, during-, and post-pandemic periods.
Interpretation: FEP incidence in South London increased during the peak of the COVID-19 pandemic, particularly among Black and Asian individuals.
Funding: None.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11876906 | PMC |
http://dx.doi.org/10.1016/j.eclinm.2025.103086 | DOI Listing |
Ann Med
December 2025
Department of Assisted Reproductive Centre, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, China.
Background: Butyrate may inhibit SARS-CoV-2 replication and affect the development of COVID-19. However, there have been no systematic comprehensive analyses of the role of butyrate metabolism-related genes (BMRGs) in COVID-19.
Methods: We performed differential expression analysis of BMRGs in the brain, liver and pancreas of COVID-19 patients and controls in GSE157852 and GSE151803.
Rev Med Virol
March 2025
Department of Periodontics, University of Illinois Chicago, Chicago, Illinois, USA.
SARS-CoV-2 is an oral pathogen that infects and replicates in mucosal and salivary epithelial cells, contributing to oral post-acute sequelae COVID-19 (PASC) and other oral and non-oral pathologies. While pre-existing inflammatory oral diseases provides a conducive environment for the virus, acute infection and persistence of SARS-CoV-2 can also results in oral microbiome dysbiosis that further worsens poor oral mucosal health. Indeed, oral PASC includes periodontal diseases, dysgeusia, xerostomia, pharyngitis, oral keratoses, and pulpitis suggesting significant bacterial contributions to SARS-CoV-2 and oral tissue tropism.
View Article and Find Full Text PDFRes Social Adm Pharm
March 2025
WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich GmbH (GÖG / Austrian National Public Health Institute), Stubenring 6, 1010, Vienna, Austria; Department of Health Policy, London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, UK. Electronic address:
Background: Community pharmacy appears to have undergone considerable change over the years.
Objectives: The objective of this research is to study the range of community pharmacy services provided in late stages of the COVID-19 pandemic and during the last decades and to identify potential drivers for change.
Methods: Four European countries (Austria, England, Estonia, and Portugal), which represent a balance in terms of income, organization of the health system and pharmacy services, were selected as case studies.
J Microbiol Immunol Infect
March 2025
Division of Pediatric Infectious Diseases, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; Chang Gung University School of Medicine, Taoyuan, Taiwan. Electronic address:
Background: Strict mask wearing and handwashing were implemented in hospital settings during COVID-19 pandemic in Taiwan. To explore if nasal methicillin-resistant Staphylococcus aureus (MRSA) carriage rate among inpatients in the hospital changed before and after COVID-19, we conducted this study.
Methods: Patients who were admitted to a regional hospital in central Taiwan during one week in 2012 and 2023, respectively, were enrolled.
Vaccine
March 2025
Robert Koch Institute, Am Nordufer 20, 13353 Berlin, Germany. Electronic address:
Introduction: As of 24 October 2021, 128,868 laboratory-confirmed COVID-19 cases and 3550 deaths were reported from Namibia. The national COVID-19 vaccination campaign that started in March 2021 included health workers (HWs) as a priority group. The vaccines most administered were Sinopharm, AstraZeneca, Pfizer-BioNtech, and Janssen.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!